OnKure Therapeutics (OKUR) Capital Expenditures (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Capital Expenditures for 7 consecutive years, with $3000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures fell 76.92% year-over-year to $3000.0; the trailing twelve-month figure through Jun 2026 stood at $23000.0 (down 64.06% YoY), and the FY2025 full-year result was $46000.0, down 11.54% from the prior year.
• Capital Expenditures retreated to $3000.0 in Q2 2026 per OKUR's latest filing, from $5000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $250000.0 in Q4 2022 and bottomed at $3000.0 in Q2 2026.
• Historically, Capital Expenditures has averaged $38777.8 across 5 years, with a median of $16500.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 300.0% in 2022, then plunged 94.77% in 2024.
• Over 5 years, Capital Expenditures stood at $250000.0 in 2022, then sank by 80.0% to $50000.0 in 2023, then plunged by 70.0% to $15000.0 in 2024, then tumbled by 40.0% to $9000.0 in 2025, then plunged by 66.67% to $3000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $3000.0, $5000.0, and $9000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.